Zanubrutinib Induced Acneiform Rash in a Patient With Waldenstrom ’s Macroglobulinemia

Rákkutatás · Waldenstrom macroglobulinemia

We report the case of an 81 year-old man with Waldenström's macroglobulinemia who developed a Grade I acneiform rash shortly after initiating zanubrutinib.

Waldenström's macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton ’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib. Although zanubrutinib is associated with fewer off-target effects than first-generation BTKi, dermatologic toxicities may still occur. We report the case of an 81 year-old man with Waldenström's macroglobulinemia who developed a Grade I acneiform rash shortly after initiating zanubrutinib. The eruption, characterised by folliculocentric papules and pustules on the face and trunk, resolved with topical azelaic acid and salicylic acid, as well as oral azithromycin. Histology showed a perivascular and periadnexal CD3+ T-cell infiltrate without epidermotropism. A Naranjo score of 8 supported a probable drug reaction. This report highlights the need for awareness of cutaneous side effects associated with newer BTKi to ensure prompt diagnosis and optimal patient management.

Acneiform rash is a dermatologic adverse event associated with zanubrutinib, a second-generation BTK inhibitor used in Waldenström’s macroglobulinemia. Recognising this toxicity enables clinicians to manage the rash conservatively without interrupting therapy, thereby avoiding unnecessary treatment delays and maintaining disease control.\n\nThe key message is that zanubrutinib can cause an acneiform rash, which can be effectively treated with topical agents and oral azithromycin, allowing continued use of the drug in patients with Waldenström's macroglobulinemia.

Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.

Eredeti forrás

Kapcsolódó jelek